DAVIS, Calif—“Unprecedented” survival times for patients with stage IIIB non–small-cell lung cancer (NSCLC) have resulted from adding taxane sequencing to combined-modality therapy with radiotherapy plus cisplatin(Drug information on cisplatin) (Platinol) and etoposide(Drug information on etoposide). These results from the Southwestern Oncology Group (SWOG) 9504 trial were presented at the ASCO meeting by David R. Gandara, MD, of the University of California Cancer Center, Davis.
The approach involved initial treatment with the combined radiation/cisplatin/etoposide regimen, followed by two sequential administrations of docetaxel(Drug information on docetaxel) (Taxotere). At a press conference, Dr. Gandara called the results “unprecedented” and reported a 1-year survival rate of 78%, a 2-year survival rate of 48%, and a median survival of 22 months.
Following surgery or radiotherapy alone, the expected survival in this group of patients is generally less than 10%. The addition of chemotherapy has improved upon this figure, but the current SWOG study achieved the most favorable survival yet, he said.
The SWOG study documented tumor stage through biopsy of the primary tumor or the lymph nodes. “Most clinical trials in stage III disease have not required this pathologic staging,” Dr. Gandara pointed out.
The Regimen
The phase II trial included 83 patients, who were treated with cisplatin 50 mg/m2 on days 1, 8, 29, and 36; with etoposide 50 mg/m2 on days 1 to 5 and 29 to 33; and with concurrent radiation (1.8 to 2.0 Gy/day) starting on day 1 (61 Gy total). This was followed by consolidation docetaxel 75 to 100 mg/m² every 21 days for three cycles.
A previous SWOG trial followed the first part of this regimen, but without docetaxel as consolidation therapy. Instead, patients were treated with additional cycles of cisplatin/etoposide. That strategy achieved a 2-year survival rate of 34% and a median survival of 15 months.
In the subsequent trial—SWOG 9504—the investigators substituted taxane sequencing for the cisplatin/etoposide follow-up dosing, based on the potential molecular mechanisms of action of the taxanes, that is, that the activity of these agents is independent of p53. It is not clear whether the excellent outcome could be attributed to docetaxel’s action specifically or to a general taxane effect, he said.
The radiographic response in 83 patients included 3 complete responses (4%) and 49 partial responses (59%). Stable disease was noted in 23 (28%), and 8 patients progressed (9%).
Therapy Well Tolerated
The treatment was relatively well tolerated. Hematologic toxicity (assessed in 69 patients after consolidation docetaxel) included grade 3-4 neutropenia in 56% of patients; however, the duration was brief and only six patients developed neutropenic fever. There was one case of grade 3 thrombocytopenia and one infection-related death. Three deaths occurred from pulmonary complications; these were possibly late radiation reactions.
The regimen is fairly easy to administer and quite well accepted by patients, Dr. Gandara noted. “We told the patients from day 1 that they would only have to receive three doses of docetaxel—one shot every 3 weeks—and at the end of the 9 weeks, they would be finished. I think they were more accepting of that sort of regimen,” he remarked at the press conference.
Since this was a nonrandomized phase II trial, Dr. Gandara said that the investigators “are cautious about being overly optimistic about the results.” He added, however, that as the 3-year follow-up approaches, few patients have died, suggesting there may be an encouraging treatment plateau.
